Table 2.

Summary of effects of somatostatin analogs and somatostatin/dopamine chimeric compounds on NET cell line proliferation and ERK1/2 phosphorylation

Compound	Action	H720	ERKp	H727	ERKp	KRJ-I	ERKp
BIM23023	sst2/5 agonist	0.23 Nm	Y	No effect	N	0.28 μM	Y
BIM23926	sst1 agonist	No effect	N	No effect	N	8.5 nM	Y
BIM23120	sst2 agonist	41 pM	Y	0.7nM	Y	No effect	N
BIM23206	sst5 agonist	2.4 pM	Y	No effect	N	No effect	N
BIM23244	sst2/5 agonist	0.11 nM	Y	No effect	N	7.4 nM	Y
Lanreotide	sst2/5 agonist	6.5 pM	Y	No effect	N	1 nM	Y
BIM23A719	pan sst agonist 1	6.2 nM		No effect		0.53 nM
BIM23A779	pan sst agonist 2	No effect		1.9pM		0.35 μM
BIM53061	Dopamine Agonist	21 nM		No effect		0.71 μM
BIM23A758	sst/da agonist 1	No effect		No effect		No effect
BIM23A760	sst/da agonist 2	18.3 nM		No effect		No effect
BIM23A761	sst/da agonist 3	4.2 nM	N	5.5 nM	N	No effect	N